VBLT Vascular Biogenics Ltd.

5.55
+1  (23%)
Previous Close 4.50
Open 5.00
Price To book 2.60
Market Cap 149.16M
Shares 26,875,000
Volume 411,895
Short Ratio 3.22
Av. Daily Volume 91,363

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met primary endpoint. Overall survival data released November 29, 2016 with full data released February 21, 2017.
VB-111
Thyroid cancer
Phase 3 trial to be initiated 2H 2017.
VB-111
Recurrent platinum resistant ovarian cancer
Phase 3 completion of enrollment announced January 6, 2017. Interim analysis due mid 2017. Full data due early 2018.
VB-111
Recurrent glioblastoma (rGBM) cancer
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Ulcerative colitis
Phase 2 failed to meet endpoints - Feb 2015 data
VB-201
Psoriasis

Latest News

  1. VBL Therapeutics to Host a Key Opinion Leader Event on Novel New Targets and Immunotherapeutic Approaches to Oncology
  2. VBL Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference
  3. VBL Therapeutics to Present at the 29th Annual ROTH Conference
  4. VBL Therapeutics to Report Full-Year 2016 Financial Results on March 27
  5. VBL Therapeutics Thyroid Cancer Drug Clears Phase 2
  6. VBL Therapeutics Reports Full Data for VB-111 Monotherapy in Phase 2 Trial for Recurrent Thyroid Cancer
  7. VBL Therapeutics to Present at the 2017 BIO CEO & Investor Conference
  8. VBL Therapeutics Announces Publication of Research on a Potential Novel Immuno-Oncology Target
  9. VBL Therapeutics Provides Year End 2016 Corporate Update
  10. VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
  11. VBL Therapeutics Announces Completion of Enrollment in the Pivotal GLOBE Study
  12. How Xenon Pharmaceuticals Inc (XENE) Stacks Up Against Its Peers
  13. Vascular Biogenics Ltd. :VBLT-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
  14. VBL Therapeutics Announces Third Quarter 2016 Financial Results and Provides Business Update
  15. VBL Therapeutics to Report Third Quarter 2016 Financial Results on November 10
  16. VBL Therapeutics Announces Plans to Establish New Manufacturing Facility
  17. Earnings Estimates Moving Higher for Vascular Biogenics (VBLT): Time to Buy?
  18. 5 Stocks Under $10 That Could Make You a Lot of Money
  19. VBL Therapeutics Announces Second Quarter 2016 Financial Results and Provides Business Update
  20. BioLineRx Names Philip A. Serlin as Chief Executive Officer